Bristol-Myers details strategy to offset future Plavix losses

03/5/2010 | Google

Bristol-Myers Squibb expects to offset losses from the looming expiration of Plavix's patent by launching some of the 60 treatments in its pipeline and through increased sales of other products. CEO James Cornelius told analysts that the company plans to get approval for several products before 2012. These could include blood thinner apixaban, organ transplant drug belatacept and skin cancer medicine ipilimumab, among other products.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Marlborough, MA
Test Technician
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT